[[{“value”:”
**Considerations for the Perfect Biomanufacturing Site**
Biomanufacturing refers to the process of using biological components such as cell lines, enzymes, or microorganisms to produce commercial products that range from pharmaceuticals to food ingredients. With increasing demand for these products, the need for specialized biomanufacturing facilities is also on the rise.
However, unlike traditional manufacturing plants, selecting a site for biomanufacturing operations requires a more tailored approach. A recent report highlights three critical factors that companies should consider when choosing a location for biomanufacturing:
**1. Labor and Infrastructure**
Biomanufacturing is both labor-intensive and resource-heavy. Facilities typically consume up to 14 times more energy than traditional manufacturing plants. Additionally, their operations generate complex wastewater that demands advanced treatment systems.
Companies also need access to a specialized workforce that includes researchers, lab technicians, and skilled manufacturing personnel. Site selection should therefore be based on data-driven decisions that evaluate labor availability and costs, supply of utilities such as power and water, and access to state and local incentives.
**2. Supply Diversification**
The COVID-19 pandemic exposed weaknesses in global supply chains, which continue to impact manufacturers, including those in the biomanufacturing industry. To mitigate these vulnerabilities and reduce dependence on international supply chains, many life sciences companies are increasing their domestic production capabilities.
This shift requires multiple U.S.-based locations, often involving concurrent site searches and capital development projects to support diversified supply chains and reduce exposure to tariffs and logistical delays.
**3. Capital Flexibility**
Biomanufacturing facilities demand significant capital investment not only in energy and workforce, but also in specialized infrastructure and equipment. Many companies prefer to own their sites outright to protect these investments and ensure continuity in production capacity.
Capital flexibility becomes essential in such scenarios. Companies often explore a variety of funding strategies such as securing new development capital, entering into sale-leaseback arrangements, or adopting other methods that can enhance liquidity and financial agility.
As the biomanufacturing sector continues to evolve, making informed, strategic choices about facility locations will be key in building resilient, efficient, and scalable operations.
“}]]
